<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fourteen children with a median age of 9.8 yr with SAA (10 males, four females) underwent related HLA identical allogeneic stem cell transplantation using Flu, Cy +/- ATG between 2004 and 2006 </plain></SENT>
<SENT sid="1" pm="."><plain>GVHD prophylaxis consisted of <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> +/- mini <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Graft source included PBSCs (seven) or BM (seven) </plain></SENT>
<SENT sid="3" pm="."><plain>One patient expired &lt;7 days post-transplant, while 12 (85.7%) patients engrafted with median neutrophil and platelet engraftment times of 13.8 and 14.5 days each </plain></SENT>
<SENT sid="4" pm="."><plain>One patient had primary graft failure and expired on Day +27 </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> GVHD was seen in 25% of evaluable patients while limited <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD was seen in 33% </plain></SENT>
<SENT sid="6" pm="."><plain>At a mean follow-up of 18 months, 12 patients (85.7%) are alive and well </plain></SENT>
<SENT sid="7" pm="."><plain>Compared with a historical cohort of 12 children transplanted using Cy/ATG, there was faster engraftment (13.8 vs. 16.4 days; p = 0.002) with lower rejection rates (7.1 vs. 36.3%; p = 0.133) and improved event free (85.7 vs. 54.5%; p = 0.177) and overall survival (85.7 vs. 63.6%; p = 0.350) </plain></SENT>
<SENT sid="8" pm="."><plain>Flu with Cy +/- ATG reduces rejection and improves overall and event free survival in children with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
</text></document>